RxDoctor Payments Data

Haley White

Family · Pell City, ALNPI 1356753347

Payments from drug & device makers

$8,855in general payments, 2019–2025

Across 595 payments — averaging $14.88 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$2K
  • AbbVie$996
  • AstraZeneca$531
  • Bayer$497
  • Lilly USA, LLC$491
  • Pfizer$458
  • plus $4K from 37 others

What the payments were for

  • Food & beverage$8,855100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$8,855 in reported general payments places this provider in the 95th percentile of 3,415 family providers in Alabama.

See all family providers in Alabama

Medicare billing

Part B allowed, 2024
$45,528
Medicare patients
120
Services billed
2,077

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide144$204,725
JardianceEmpagliflozin105$100,999
Trelegy ElliptaFluticasone/Umeclidin/Vilanter143$92,294
EliquisApixaban74$68,312
FarxigaDapagliflozin Propanediol84$67,267
OtezlaApremilast13$63,599
MounjaroTirzepatide36$43,172
RybelsusSemaglutide22$39,076
LinzessLinaclotide45$35,242
Soliqua 100-33Insulin Glargine/Lixisenatide37$32,051
XareltoRivaroxaban31$30,717
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr43$22,079
JanuviaSitagliptin Phosphate17$21,025
Tresiba Flextouch U-200Insulin Degludec11$16,036
Xultophy 100-3.6Insulin Degludec/Liraglutide12$14,382

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus, Xultophy 100-3.6$1,648$258,183178 claims
GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta$414$124,065205 claims
Boehringer IngelheimJardiance$163$100,999105 claims
AstraZenecaFarxiga, Symbicort$531$71,391102 claims
PfizerEliquis$458$68,31274 claims
AmgenOtezla$390$63,59913 claims
Lilly USA, LLCMounjaro$491$43,17236 claims
AbbVieLinzess$996$35,24245 claims
Sanofi-aventis U.S. LLCSoliqua 100-33$209$32,05137 claims
Johnson & JohnsonXarelto$143$30,71731 claims
MerckJanuvia$347$21,02517 claims
NovartisEntresto$210$6,28319 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 3,415 family providers in Alabama.

Other family in Pell City

See the full list for Alabama

Where these figures come from

Is this you, or does something look wrong? →